olaparib
merck,astrazeneca
['ovarian', 'brca', 'solo-1', 'lynparza']
in solo-1 phase iii trial, lynparza improved overall survival versus placebo in patients with brca mutated newly diagnosed advanced ovarian cancer. #esmo22 #esmo2022 #onctwitter #medtwitter #cancer #oncology #cancerresearch #cancertreatment #cancercare
iPharmaCenter is a #website which covers #pharmaceutical and #healthcare #news plus #blogs #diseases #drugs #healthcaresystems #globalhealth #pharma